Vaishali Pharma quarterly results

·UnclassifiedChart ›

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Year before	Change
Revenue	22.9	—	—
EBITDA	1.5	—	—
EBITDA margin	6.5%	—	—
Profit before tax	1.7	—	—
Net profit	1.5	—	—
EPS	₹0.12	—	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025

Expenses
	22.9	26.9	24.7	33.4
	0.6	1.3	0.9	0.8
	23.5	28.2	25.5	34.3
	17.3	27.3	19.6	28.0
	2.1	−2.9	1.4	1.7
	0.7	0.8	0.7	0.6
	0.2	0.7	0.5	0.4
	0.1	0.2	0.1	0.2
	1.2	1.9	1.4	1.7
	21.7	28.0	23.7	32.6
	1.5	−0.2	1.6	1.4
	1.3	−0.4	1.4	1.2
Profit
	1.7	0.2	1.8	1.7
	1.7	0.2	1.8	1.7
	0.4	0.0	0.4	0.4
	−0.1	−0.1	0.1	0.0
	0.2	−0.1	0.5	0.5
	0.1	0.1	0.0	0.0
	1.5	0.4	1.3	1.2
	1.5	0.3	1.3	1.2
	−0.0	0.0	0.0	0.0
	1.5	0.4	1.3	1.2
Per share
	₹0.12	₹0.03	₹0.10	₹0.09
	₹0.12	₹0.03	₹0.10	₹0.09
Other comprehensive income — detail
	−0.0	0.0	—	—
	—	0.0	—	—
	—	0.0	—	—
	−0.0	—	—	—
Per share — as-filed variants
	₹0.12	₹0.03	₹0.10	₹0.09
	₹0.12	₹0.03	₹0.10	₹0.09
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	3.5	2.5	3.7	3.7
	15.1%	9.2%	15.1%	11.2%
Adjusted (ex-exceptional items) — derived
	1.7	0.2	1.8	1.7
	1.5	0.4	1.3	1.2
	₹0.12	₹0.03	₹0.10	₹0.09

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VAISHALI₹6.82

Vaishali Pharma Limited

· Unclassified

Annual Quarterly₹ CrorePeersTEMBO TOTAL OSWALSEEDS GROBTEA BEARDSELL HINDCON CROWN ARTNIRMANMcap ₹44.5 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	33.4	24.7	26.9	22.9
Other Income	0.8	0.9	1.3	0.6
Total Income	34.3	25.5	28.2	23.5
Expenses
+ Purchases of Stock-in-Trade	28.0	19.6	27.3	17.3
+ Changes in Inventories	1.7	1.4	-2.9	2.1
+ Employee Benefit Expense	0.6	0.7	0.8	0.7
+ Finance Costs	0.4	0.5	0.7	0.2
+ Depreciation & Amortisation	0.2	0.1	0.2	0.1
+ Other Expenses	1.7	1.4	1.9	1.2
Total Expenses	32.6	23.7	28.0	21.7
EBITDA	1.4	1.6	-0.2	1.5
EBIT	1.2	1.4	-0.4	1.3
Profit
PBT before Exceptional Items	1.7	1.8	0.2	1.7
Pretax Income	1.7	1.8	0.2	1.7
+ Current Tax	0.4	0.4	0.0	0.4
+ Deferred Tax	0.0	0.1	-0.1	-0.1
Tax Expense	0.5	0.5	-0.1	0.2
+ Share of Associates & JVs	0.0	0.0	0.1	0.1
Net Income	1.2	1.3	0.4	1.5
+ Net Income — Continuing Ops	1.2	1.3	0.3	1.5
+ Other Comprehensive Income	0.0	0.0	0.0	-0.0
Total Comprehensive Income	1.2	1.3	0.4	1.5
Per Share
Basic EPS	0.09	0.10	0.03	0.12
Diluted EPS	0.09	0.10	0.03	0.12
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	0.0	-0.0
+ Items NOT to be Reclassified to P&L	—	—	0.0	—
+ Tax on Items NOT to be Reclassified	—	—	0.0	—
+ Items to be Reclassified to P&L	—	—	—	-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.09	0.10	0.03	0.12
Diluted EPS — Continuing Operations	0.09	0.10	0.03	0.12
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	3.7	3.7	2.5	3.5
Gross Margin %	11.21	15.07	9.17	15.07
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	1.7	1.8	0.2	1.7
Net Income Adj (tax-effected)	1.2	1.3	0.4	1.5
EPS Adj	0.09	0.10	0.03	0.12
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00
Paid Up Equity Capital	13.0	26.1	13.0	13.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Vaishali Pharma quarterly results

Vaishali Pharma (NSE: VAISHALI) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹1.5 crore, up 305.9% from ₹38 lakh in Q4 FY26. Revenue from operations was ₹22.9 crore, down 15.0% from the previous quarter.

Q2 FY26 results (a year earlier): 14 November 2025
Q1 FY27 results (the latest): 14 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net profit: ₹1.5 Cr+305.9% vs Q4 FY26
Q1 FY27 revenue: ₹22.9 Cr−15.0% vs Q4 FY26
Q1 FY27 operating margin: 5.9%+7.2 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹1.2 CrRevenue ₹33.4 Cr
Q1 FY27 EPS (basic): ₹0.12

Questions

When will Vaishali Pharma announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 14 November 2025.

What will Vaishali Pharma's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹1.2 crore and revenue from operations ₹33.4 crore. The latest quarter, Q1 FY27, had a net profit of ₹1.5 crore and revenue of ₹22.9 crore.

How has Vaishali Pharma's profit changed over the last four quarters?

Net profit by quarter: ₹1.2 crore in Q2 FY26, ₹1.3 crore in Q3 FY26, ₹38 lakh in Q4 FY26 and ₹1.5 crore in Q1 FY27. That is ₹4.4 crore over the four quarters. Revenue from operations: ₹33.4 crore, ₹24.7 crore, ₹26.9 crore and ₹22.9 crore.

What were Vaishali Pharma's Q1 FY27 results?

Consolidated net profit was ₹1.5 crore, up 305.9% from ₹38 lakh in Q4 FY26. Revenue from operations was ₹22.9 crore, down 15.0% from the previous quarter.

What was Vaishali Pharma's net profit in FY26?

Consolidated net profit was ₹4.2 crore in FY26 (April 2025–March 2026).

What was Vaishali Pharma's revenue in FY26?

Revenue from operations was ₹109 crore in FY26 (April 2025–March 2026).

Where do these Vaishali Pharma figures come from?

From Vaishali Pharma's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.